Banner NPRA

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Actemra® (tocilizumab): New important identified risk of hepatotoxicity

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif
 

 

Description:

Actemra® (tocilizumab) is a biological product indicated for rheumatoid arthritis in adults, polyarticular systemic juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in patients above 2 years old, as well as giant cell arteritis (GCA) in adults.

 

Serious drug-induced liver injury, including acute liver failure, hepatitis and jaundice, which in some cases required liver transplant, have been observed with the use of Actemra®.

Several measures should be considered in patients receiving Actemra®, as follows:

  • All healthcare professionals are advised to monitor the ALT and AST levels of their patients every 4 to 8 weeks for the first 6 months of Actemra® treatment, followed by every 12 weeks thereafter for all approved indications.
  • Exercise caution when initiating Actemra® treatment in patients with ALT or AST >1.5 times the upper limit of normal (ULN). Treatment is not recommended in patients with ALT or AST >5 times ULN.
  • Recommended dose modifications of Actemra® due to the liver enzyme abnormalities remain unchanged. Please refer to the product information for full prescribing details.

 

NPRA has approved a Direct Healthcare Professional Communication (DHPC) letter issued by Roche (Malaysia) Sdn. Bhd. to highlight this safety issue. For further information, please contact your local sales person for a copy of the DHPC.

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Jumaat 06 Disember 2024, 15:23:03.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search

Menu Utama